TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-Blind Study With an Active-Controlled Initial Treatment Period Followed by a Dose-Blind Maintenance Treatment Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Brief Summary: This is a study to compare the efficacy of bimekizumab versus adalimumab in the treatment of subjects with moderate to severe chronic plaque psoriasis (PSO).


Options:
A: Arm Label: Placebo-controlled Phase:; Type: EXPERIMENTAL; Interventions: Other: Placebo | Arm Label: Placebo-controlled Phase: Apremilast 30 mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast | Arm Label: Extension Phase: Apremilast 30 mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): Extension Phase: Apremilast 30 mg, Placebo-controlled Phase: Apremilast 30 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo-controlled Phase:
B: Arm Label: Bimekizumab Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab, Other: Placebo | Arm Label: Bimekizumab Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab, Other: Placebo | Arm Label: Adalimumab Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bimekizumab, Drug: Adalimumab, Other: Placebo | Intervention Type: DRUG; Name: Bimekizumab; Assigned to Arm(s): Adalimumab Arm, Bimekizumab Arm 1, Bimekizumab Arm 2 | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Adalimumab Arm | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Adalimumab Arm, Bimekizumab Arm 1, Bimekizumab Arm 2
C: Arm Label: Adalimumab (Part A); Type: ACTIVE_COMPARATOR; Interventions: Biological: adalimumab, Drug: placebo for risankizumab | Arm Label: Risankizumab (Part A); Type: EXPERIMENTAL; Interventions: Drug: risankizumab, Biological: placebo for adalimumab | Intervention Type: DRUG; Name: risankizumab; Assigned to Arm(s): Risankizumab (Part A) | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Adalimumab (Part A) | Intervention Type: DRUG; Name: placebo for risankizumab; Assigned to Arm(s): Adalimumab (Part A) | Intervention Type: BIOLOGICAL; Name: placebo for adalimumab; Assigned to Arm(s): Risankizumab (Part A)
D: Arm Label: Group Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: Adalimumab | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Adalimumab, Other: Placebo | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Group Adalimumab, Placebo Group | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of a Mobile Phone Text Messages Intervention on the Secondary Prevention of Cardiovascular Events After Acute Coronary Syndrome
Brief Summary: The study is a two-arm, parallel, randomized clinical trial. The purpose of the study is to evaluate the effectiveness of automated mobile phone text message-based intervention for secondary prevention after acute coronary syndrome hospitalization. Text messages will include information about lifestyle modifications, medication adherence and cardiovascular risk factor control. The participants will be randomized into intervention and control groups in a 1:1 ratio. The intervention group will receive 4 pre-designed and semi-personalized text messages per week in addition to usual care for 6 months, while the control group will receive usual care.


Options:
A: Arm Label: Text Message Group; Type: EXPERIMENTAL; Interventions: Behavioral: Text Message, Other: Website | Arm Label: Application Group; Type: EXPERIMENTAL; Interventions: Behavioral: Mobile Application, Other: Website | Arm Label: Website-Control; Type: EXPERIMENTAL; Interventions: Other: Website | Intervention Type: BEHAVIORAL; Name: Text Message; Assigned to Arm(s): Text Message Group | Intervention Type: BEHAVIORAL; Name: Mobile Application; Assigned to Arm(s): Application Group | Intervention Type: OTHER; Name: Website; Assigned to Arm(s): Application Group, Text Message Group, Website-Control
B: Arm Label: SINEMA intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: SINEMA intervention | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: SINEMA intervention; Assigned to Arm(s): SINEMA intervention group
C: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Generic Nudge; Type: EXPERIMENTAL; Interventions: Behavioral: Nudge | Arm Label: Optimized nudge; Type: EXPERIMENTAL; Interventions: Behavioral: Nudge | Arm Label: Optimized nudge plus AI Chat Bot; Type: EXPERIMENTAL; Interventions: Behavioral: Nudge | Intervention Type: BEHAVIORAL; Name: Nudge; Assigned to Arm(s): Generic Nudge, Optimized nudge, Optimized nudge plus AI Chat Bot
D: Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Behavioral: Mobile phone text message | Arm Label: No Intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mobile phone text message; Assigned to Arm(s): Experimental

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of a Mobile Phone Text Messages Intervention on the Secondary Prevention of Cardiovascular Events After Acute Coronary Syndrome
Brief Summary: The study is a two-arm, parallel, randomized clinical trial. The purpose of the study is to evaluate the effectiveness of automated mobile phone text message-based intervention for secondary prevention after acute coronary syndrome hospitalization. Text messages will include information about lifestyle modifications, medication adherence and cardiovascular risk factor control. The participants will be randomized into intervention and control groups in a 1:1 ratio. The intervention group will receive 4 pre-designed and semi-personalized text messages per week in addition to usual care for 6 months, while the control group will receive usual care.


Options:
A: Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Behavioral: Mobile phone text message | Arm Label: No Intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mobile phone text message; Assigned to Arm(s): Experimental
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Do CHANGE | Arm Label: Care as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Do CHANGE; Assigned to Arm(s): Intervention
C: Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Other: Exercise-based cardiac rehabilitation program | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise-based cardiac rehabilitation program; Assigned to Arm(s): Experimental group
D: Intervention Type: BEHAVIORAL; Name: exercise training; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vitamin D Intervention in Children With Sickle Cell Disease: A Pilot Randomized Controlled Trial
Brief Summary: Sickle cell disease (SCD) is a genetic disease characterized by abnormal hemoglobin, the main constituent of red blood cells. People with SCD have nutritional deficiencies, and vitamin D deficiency is one of the most common. Symptoms of vitamin D deficiency are similar to those of SCD and include chronic pain and bone complications. Correcting vitamin D nutrition of children with SCD represents a treatment that will improve their health. A single oral high-dose of vitamin D3 will be given to SCD children during one of their follow-up visits at the SCD clinic of CHU Sainte-Justine, Montreal, Canada. This mode of administration was chosen to ensure a better adherence to the treatment. The investigators will determine whether this dose is safe and its administration feasible in clinic. The impact of this dose on blood vitamin D and calcium, urinary calcium, growth, inflammation, bone health, pain and quality of life will also be assessed. This study intends to propose a new intervention to improve the nutrition of children with this disease.


Options:
A: Arm Label: investigational product; Type: EXPERIMENTAL; Interventions: Drug: L-glutamine | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: L-glutamine; Assigned to Arm(s): investigational product | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Vitamin D bolus; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D bolus | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D bolus; Assigned to Arm(s): Vitamin D bolus | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Folic Acid Supplement [Phase 1]; Type: OTHER; Interventions: Dietary Supplement: Folic Acid Supplement, Dietary Supplement: Placebo | Arm Label: Placebo [Phase 1]; Type: OTHER; Interventions: Dietary Supplement: Folic Acid Supplement, Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Folic Acid Supplement; Assigned to Arm(s): Folic Acid Supplement [Phase 1], Placebo [Phase 1] | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Folic Acid Supplement [Phase 1], Placebo [Phase 1]
D: Arm Label: Zinc; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Zinc | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Zinc; Assigned to Arm(s): Zinc | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Research Evaluating the EffectiVeness of Adding an Internet-Based Self-Management Intervention to Usual Care in the Treatment of Borderline Personality Disorder - REVISIT BPD
Brief Summary: The trial aims to evaluate the effectiveness of a novel internet intervention (Priovi), which was designed to introduce relevant schema therapy techniques to Persons with Borderline Personality Disorder (BPD). Therefore, 200 people with BPD will be recruited and randomized to two groups: (1) a control group, in which they may engage with any BPD treatment (Care-as-Usual, CAU) and receive access to Priovi after a delay of 12 months (i.e., CAU/wait list control group), or (2) to a treatment group that immediately receives 12-month access to Priovi and may also use CAU. The primary outcome measure is the score of the Borderline Personality Disorder Severity Index (BPDSI), collected at three, six and 12 month post-baseline.


Options:
A: Intervention Type: DRUG; Name: Topiramate; Assigned to Arm(s): N/A
B: Arm Label: Priovi; Type: EXPERIMENTAL; Interventions: Behavioral: Priovi, Other: CAU | Arm Label: Care-as-Usual (CAU) / wait list; Type: ACTIVE_COMPARATOR; Interventions: Other: CAU | Intervention Type: BEHAVIORAL; Name: Priovi; Assigned to Arm(s): Priovi | Intervention Type: OTHER; Name: CAU; Assigned to Arm(s): Care-as-Usual (CAU) / wait list, Priovi
C: Arm Label: General Psychiatric Management (GPM; Gunderson & Links, 2008); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Psychiatric Management | Arm Label: GPM plus Motive-Oriented Therapeutic Relationship; Type: EXPERIMENTAL; Interventions: Behavioral: Psychiatric Management, Behavioral: Motive-oriented therapeutic relationship/Plan Analysis | Intervention Type: BEHAVIORAL; Name: Psychiatric Management; Assigned to Arm(s): GPM plus Motive-Oriented Therapeutic Relationship, General Psychiatric Management (GPM; Gunderson & Links, 2008) | Intervention Type: BEHAVIORAL; Name: Motive-oriented therapeutic relationship/Plan Analysis; Assigned to Arm(s): GPM plus Motive-Oriented Therapeutic Relationship
D: Intervention Type: BEHAVIORAL; Name: Dialectical Behavioral Therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Research Evaluating the EffectiVeness of Adding an Internet-Based Self-Management Intervention to Usual Care in the Treatment of Borderline Personality Disorder - REVISIT BPD
Brief Summary: The trial aims to evaluate the effectiveness of a novel internet intervention (Priovi), which was designed to introduce relevant schema therapy techniques to Persons with Borderline Personality Disorder (BPD). Therefore, 200 people with BPD will be recruited and randomized to two groups: (1) a control group, in which they may engage with any BPD treatment (Care-as-Usual, CAU) and receive access to Priovi after a delay of 12 months (i.e., CAU/wait list control group), or (2) to a treatment group that immediately receives 12-month access to Priovi and may also use CAU. The primary outcome measure is the score of the Borderline Personality Disorder Severity Index (BPDSI), collected at three, six and 12 month post-baseline.


Options:
A: Arm Label: Dialectical Behavior Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Dialectical Behaviour Therapy | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dialectical Behaviour Therapy; Assigned to Arm(s): Dialectical Behavior Therapy
B: Arm Label: Priovi; Type: EXPERIMENTAL; Interventions: Behavioral: Priovi, Other: CAU | Arm Label: Care-as-Usual (CAU) / wait list; Type: ACTIVE_COMPARATOR; Interventions: Other: CAU | Intervention Type: BEHAVIORAL; Name: Priovi; Assigned to Arm(s): Priovi | Intervention Type: OTHER; Name: CAU; Assigned to Arm(s): Care-as-Usual (CAU) / wait list, Priovi
C: Arm Label: meditation; Type: EXPERIMENTAL; Interventions: Behavioral: Central Meditation and Imagery Therapy | Arm Label: wait list; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Central Meditation and Imagery Therapy; Assigned to Arm(s): meditation
D: Arm Label: Relaxation group; Type: ACTIVE_COMPARATOR; Interventions: Other: Relaxation group | Arm Label: Psychoeducational group; Type: EXPERIMENTAL; Interventions: Behavioral: Interventional group : PEPSUI psychoeducational program | Intervention Type: BEHAVIORAL; Name: Interventional group : PEPSUI psychoeducational program; Assigned to Arm(s): Psychoeducational group | Intervention Type: OTHER; Name: Relaxation group; Assigned to Arm(s): Relaxation group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Research Evaluating the EffectiVeness of Adding an Internet-Based Self-Management Intervention to Usual Care in the Treatment of Borderline Personality Disorder - REVISIT BPD
Brief Summary: The trial aims to evaluate the effectiveness of a novel internet intervention (Priovi), which was designed to introduce relevant schema therapy techniques to Persons with Borderline Personality Disorder (BPD). Therefore, 200 people with BPD will be recruited and randomized to two groups: (1) a control group, in which they may engage with any BPD treatment (Care-as-Usual, CAU) and receive access to Priovi after a delay of 12 months (i.e., CAU/wait list control group), or (2) to a treatment group that immediately receives 12-month access to Priovi and may also use CAU. The primary outcome measure is the score of the Borderline Personality Disorder Severity Index (BPDSI), collected at three, six and 12 month post-baseline.


Options:
A: Arm Label: Mindfulness training; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness training | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mindfulness training; Assigned to Arm(s): Mindfulness training
B: Arm Label: Dynamic Cognitive Intervention Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dynamic Cognitive Intervention Group | Arm Label: No Additional Intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dynamic Cognitive Intervention Group; Assigned to Arm(s): Dynamic Cognitive Intervention Group
C: Arm Label: Priovi; Type: EXPERIMENTAL; Interventions: Behavioral: Priovi, Other: CAU | Arm Label: Care-as-Usual (CAU) / wait list; Type: ACTIVE_COMPARATOR; Interventions: Other: CAU | Intervention Type: BEHAVIORAL; Name: Priovi; Assigned to Arm(s): Priovi | Intervention Type: OTHER; Name: CAU; Assigned to Arm(s): Care-as-Usual (CAU) / wait list, Priovi
D: Arm Label: dialectical behavior therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Dialectical behavior therapy | Arm Label: treatment as usual; Type: PLACEBO_COMPARATOR; Interventions: Other: Treatment as Usual: any other drug or psychotherapy offered to participants, except DBT | Arm Label: Receiving no treatment at all; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dialectical behavior therapy; Assigned to Arm(s): dialectical behavior therapy | Intervention Type: OTHER; Name: Treatment as Usual: any other drug or psychotherapy offered to participants, except DBT; Assigned to Arm(s): treatment as usual

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Research Evaluating the EffectiVeness of Adding an Internet-Based Self-Management Intervention to Usual Care in the Treatment of Borderline Personality Disorder - REVISIT BPD
Brief Summary: The trial aims to evaluate the effectiveness of a novel internet intervention (Priovi), which was designed to introduce relevant schema therapy techniques to Persons with Borderline Personality Disorder (BPD). Therefore, 200 people with BPD will be recruited and randomized to two groups: (1) a control group, in which they may engage with any BPD treatment (Care-as-Usual, CAU) and receive access to Priovi after a delay of 12 months (i.e., CAU/wait list control group), or (2) to a treatment group that immediately receives 12-month access to Priovi and may also use CAU. The primary outcome measure is the score of the Borderline Personality Disorder Severity Index (BPDSI), collected at three, six and 12 month post-baseline.


Options:
A: Arm Label: Brexpiprazole 2-3 Milligrams Per Day; Type: EXPERIMENTAL; Interventions: Drug: Brexpiprazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Brexpiprazole; Assigned to Arm(s): Brexpiprazole 2-3 Milligrams Per Day | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Priovi; Type: EXPERIMENTAL; Interventions: Behavioral: Priovi, Other: CAU | Arm Label: Care-as-Usual (CAU) / wait list; Type: ACTIVE_COMPARATOR; Interventions: Other: CAU | Intervention Type: BEHAVIORAL; Name: Priovi; Assigned to Arm(s): Priovi | Intervention Type: OTHER; Name: CAU; Assigned to Arm(s): Care-as-Usual (CAU) / wait list, Priovi
C: Arm Label: General Psychiatric Management (GPM; Gunderson & Links, 2008); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Psychiatric Management | Arm Label: GPM plus Motive-Oriented Therapeutic Relationship; Type: EXPERIMENTAL; Interventions: Behavioral: Psychiatric Management, Behavioral: Motive-oriented therapeutic relationship/Plan Analysis | Intervention Type: BEHAVIORAL; Name: Psychiatric Management; Assigned to Arm(s): GPM plus Motive-Oriented Therapeutic Relationship, General Psychiatric Management (GPM; Gunderson & Links, 2008) | Intervention Type: BEHAVIORAL; Name: Motive-oriented therapeutic relationship/Plan Analysis; Assigned to Arm(s): GPM plus Motive-Oriented Therapeutic Relationship
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lamotrigine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lamotrigine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label, Multicenter Study to Investigate the Efficacy and Safety of Oral Molidustat in Peritoneal Dialysis Subjects With Renal Anemia
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of molidustat in peritoneal dialysis subjects with renal anemia


Options:
A: Arm Label: Participants receiving Daprodustat; Type: EXPERIMENTAL; Interventions: Drug: Daprodustat, Drug: Acetylcholine, Drug: Sodium nitroprusside, Drug: L-N-monomethyl arginine acetate (L-NMMA) | Arm Label: Participants receiving Darbepoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa, Drug: Acetylcholine, Drug: Sodium nitroprusside, Drug: L-N-monomethyl arginine acetate (L-NMMA) | Intervention Type: DRUG; Name: Daprodustat; Assigned to Arm(s): Participants receiving Daprodustat | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Participants receiving Darbepoetin alfa | Intervention Type: DRUG; Name: Acetylcholine; Assigned to Arm(s): Participants receiving Daprodustat, Participants receiving Darbepoetin alfa | Intervention Type: DRUG; Name: Sodium nitroprusside; Assigned to Arm(s): Participants receiving Daprodustat, Participants receiving Darbepoetin alfa | Intervention Type: DRUG; Name: L-N-monomethyl arginine acetate (L-NMMA); Assigned to Arm(s): Participants receiving Daprodustat, Participants receiving Darbepoetin alfa
B: Arm Label: BAY85-3934 (25mg); Type: EXPERIMENTAL; Interventions: Drug: BAY85-3934 | Arm Label: BAY85-3934 (50mg); Type: EXPERIMENTAL; Interventions: Drug: BAY85-3934 | Arm Label: BAY85-3934 (75mg); Type: EXPERIMENTAL; Interventions: Drug: BAY85-3934 | Arm Label: Darbepoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Biological: Darbepoetin alfa | Intervention Type: DRUG; Name: BAY85-3934; Assigned to Arm(s): BAY85-3934 (25mg), BAY85-3934 (50mg), BAY85-3934 (75mg) | Intervention Type: BIOLOGICAL; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa
C: Arm Label: ASP1517 Low dose group; Type: EXPERIMENTAL; Interventions: Drug: roxadustat | Arm Label: ASP1517 Middle dose group; Type: EXPERIMENTAL; Interventions: Drug: roxadustat | Arm Label: ASP1517 High dose group; Type: EXPERIMENTAL; Interventions: Drug: roxadustat | Arm Label: Darbepoetin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: darbepoetin alfa | Intervention Type: DRUG; Name: roxadustat; Assigned to Arm(s): ASP1517 High dose group, ASP1517 Low dose group, ASP1517 Middle dose group | Intervention Type: DRUG; Name: darbepoetin alfa; Assigned to Arm(s): Darbepoetin group
D: Arm Label: Molidustat (BAY85-3934); Type: EXPERIMENTAL; Interventions: Drug: Molidustat (BAY85-3934) | Intervention Type: DRUG; Name: Molidustat (BAY85-3934); Assigned to Arm(s): Molidustat (BAY85-3934)

Answer: D